×
About 1,670 results

ALLMedicine™ Chordoma Center

Research & Reviews  633 results

Children and Adults With Chordoma
https://clinicaltrials.gov/ct2/show/NCT03910465

May 13th, 2022 - Background: Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordoma...

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
https://clinicaltrials.gov/ct2/show/NCT01200680

May 13th, 2022 - Synopsis Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than fema...

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
https://clinicaltrials.gov/ct2/show/NCT05041127

May 9th, 2022 - Primary Objective: • To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or metastatic, chordoma based on response rate according to RECIST1.1. Secondary Objectives: To evaluate response rate according to Choi criteria T...

LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant ch...
https://doi.org/10.1007/s11060-022-04012-9 10.1023/A:1008947301735 10.1002/hed.23415 10.2106/00004623-198163030-00035 10.1016/j.amjoto.2013.12.018 10.1016/S1470-2045(11)70337-0 10.1016/j.wneu.2021.09.027 10.1002/cncr.28032 10.1016/j.wneu.2017.06.106 10.18632/oncotarget.3083 10.1016/j.yexcr.2005.12.016 10.1016/j.yexmp.2015.11.031 10.3892/or.2012.2199 10.1136/gut.2009.202739 10.1016/j.canlet.2016.01.008 10.1016/j.yexcr.2005.12.016 10.1038/sj.bjc.6603545 10.3892/ijo.2015.2923 10.1016/j.ejca.2012.09.032 10.1158/0008-5472.CAN-14-2040 10.1007/s00432-014-1759-3 10.3389/fonc.2018.00391 10.1186/1476-4598-7-31 10.1387/ijdb.072435nh 10.1006/geno.1995.1163 10.3892/ijo.2014.2268 10.1038/modpathol.2008.144 10.1371/journal.pone.0083187 10.4103/sni.sni_399_16 10.1242/jcs.00174 10.1007/BF03401929 10.1371/journal.pone.0035340 10.1016/j.febslet.2006.04.082 10.1186/1471-2407-7-198 10.1016/j.urolonc.2012.02.002 10.1158/0008-5472.CAN-10-0592 10.1038/onc.2012.216 10.1038/nrm1499 10.1021/bi961149j 10.1038/onc.2015.166 10.2174/15680096113136660102 10.4161/cam.4.2.10943 10.5858/arpa.2020-0258-RA
Journal of Neuro-oncology; Vanderheijden C, Vaessen T et. al.

May 5th, 2022 - Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to prom...

Chordoma
http://emedicine.medscape.com/article/250902-overview

May 3rd, 2022 - Practice Essentials A chordoma is a low-grade, slow-growing, but locally invasive and locally aggressive tumor. Chordomas belong to the sarcoma family of tumors. They arise from remnants of the notochord and occur in the midline along the spinal a...

see more →

Guidelines  1 results

Bone cancer.
https://doi.org/10.6004/jnccn.2013.0088
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 8th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

see more →

Clinicaltrials.gov  14 results

Children and Adults With Chordoma
https://clinicaltrials.gov/ct2/show/NCT03910465

May 13th, 2022 - Background: Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordoma...

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
https://clinicaltrials.gov/ct2/show/NCT01200680

May 13th, 2022 - Synopsis Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than fema...

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
https://clinicaltrials.gov/ct2/show/NCT05041127

May 9th, 2022 - Primary Objective: • To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or metastatic, chordoma based on response rate according to RECIST1.1. Secondary Objectives: To evaluate response rate according to Choi criteria T...

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
https://clinicaltrials.gov/ct2/show/NCT03623854

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To assess the clinical benefit of the combination of nivolumab and relatlimab in patients with advanced chordomas by objective response rate (ORR). SECONDARY OBJECTIVES: I. Ascertain the safety of nivolumab in combination wi...

BN Brachyury and Radiation in Chordoma
https://clinicaltrials.gov/ct2/show/NCT03595228

Feb 28th, 2022 - The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activit...

see more →

News  13 results

Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-tazemetostat-in-pediatric-patients-with-ini1negative-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients w...

Dr. Chi Discusses Pediatric Atypical Teratoid Rhabdoid Tumors
https://www.onclive.com/view/dr-chi-discusses-pediatric-atypical-teratoid-rhabdoid-tumors

Oct 6th, 2021 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors (ATRTs). A...

Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors
https://www.onclive.com/view/tazemetostat-shows-antitumor-activity-in-ini1negative-pediatric-tumors

Dec 20th, 2020 - Susan N. Chi, MD Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors, according to results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.1 In the dose-...

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors
https://www.onclive.com/view/dr-chi-on-study-of-tazemetostat-in-children-with-ini1negative-tumors

Dec 20th, 2020 - Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children...

Lead Investigator Discusses Tazemetostat Data in INI1-Negative Pediatric Tumors
https://www.onclive.com/view/lead-investigator-discusses-tazemetostat-data-in-ini1negative-pediatric-tumors

Dec 4th, 2020 - Susan N. Chi, MD Tazemetostat showed promising antitumor activity in pediatric patients with INI1-negative rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma tumors, according to findings presented at the 2018 ASPHO Conference. ...

see more →

Patient Education  7 results see all →